Hypoparathyroidism – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Hypoparathyroidism – Pipeline Review, H2 2020’, provides an overview of the Hypoparathyroidism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypoparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypoparathyroidism and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Hypoparathyroidism

– The report reviews pipeline therapeutics for Hypoparathyroidism by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Hypoparathyroidism therapeutics and enlists all their major and minor projects

– The report assesses Hypoparathyroidism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Hypoparathyroidism

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hypoparathyroidism

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hypoparathyroidism pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aerami Therapeutics

Amolyt Pharma

Ascendis Pharma A/S

BridgeBio Pharma Inc

Chugai Pharmaceutical Co Ltd

Eli Lilly and Co

Entera Bio Ltd

Extend Biosciences Inc

GC Pharma

ProLynx LLC

Sigilon Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hypoparathyroidism - Overview

Hypoparathyroidism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hypoparathyroidism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hypoparathyroidism - Companies Involved in Therapeutics Development

Aerami Therapeutics

Amolyt Pharma

Ascendis Pharma A/S

BridgeBio Pharma Inc

Chugai Pharmaceutical Co Ltd

Eli Lilly and Co

Entera Bio Ltd

Extend Biosciences Inc

GC Pharma

ProLynx LLC

Sigilon Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Hypoparathyroidism - Drug Profiles

ACP-014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aerami-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZP-3601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLTX-305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

encaleret - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXT-607 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-6272K - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

parathyroid hormone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PCO-371 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-134 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SIG-010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SIG-012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem cell Therapy for Hypoparathyroidism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teriparatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hypoparathyroidism - Dormant Projects

Hypoparathyroidism - Product Development Milestones

Featured News & Press Releases

Oct 23, 2020: Ascendis Pharma receives Orphan Designation for TransCon PTH for treatment of hypoparathyroidism in Europe

Oct 14, 2020: Amolyt Pharma doses first subject in phase 1 clinical trial of parathyroid hormone analog, AZP-3601, for Hypoparathyroidism

Sep 28, 2020: Ascendis Pharma announces preliminary six-month data from open-label extension of phase 2 PaTH forward trial and files IND amendment to initiate phase 3 PaTHway trial of TransCon PTH in adult hypoparathyroidism

Sep 21, 2020: BridgeBio Pharma’s Calcilytix Therapeutics initiates phase 2 study of encaleret for Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Sep 04, 2020: Ascendis Pharma announces presentations for TransCon PTH and hypoparathyroidism at 22nd European Congress of Endocrinology

Jul 07, 2020: ProLynx announces SBIR grant award to develop long-acting parathyroid hormone for hypo-parathyroidism

Apr 19, 2020: Ascendis Pharma announces top-line data from fixed dose portion of phase 2 trial demonstrating potential of TransCon PTH as a replacement therapy for Hypoparathyroidism

Nov 14, 2019: Ascendis Pharma expands TransCon PTH Phase 2 PaTH forward clinical trial to expedite enrollment of subjects previously treated with NATPARA in the United States

Oct 18, 2019: Leahy, Sanders, Welch urge FDA to swiftly resolve critical drug recall

Sep 23, 2019: Entera Bio reports positive results from a phase 2 PK/PD study of Oral PTH (1-34) in patients with Hypoparathyroidism

Sep 06, 2019: Takeda Issues US Recall of NATPARA (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate

May 15, 2019: Takeda to highlight new research into the long-term complications of chronic hypoparathyroidism at the European Congress of Endocrinology 2019 Annual Meeting

Apr 24, 2019: Ascendis Pharma announces presentations related to TransCon PTH at upcoming Medical Conferences

Mar 26, 2019: Takeda presents new data at the Endocrine Society’s 2019 Annual Meeting about the patient burden and long-term impact of chronic hypoparathyroidism

Mar 26, 2019: Ascendis Pharma reports positive results from heiGHt trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hypoparathyroidism, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Hypoparathyroidism – Pipeline by Aerami Therapeutics, H2 2020

Hypoparathyroidism – Pipeline by Amolyt Pharma, H2 2020

Hypoparathyroidism – Pipeline by Ascendis Pharma A/S, H2 2020

Hypoparathyroidism – Pipeline by BridgeBio Pharma Inc, H2 2020

Hypoparathyroidism – Pipeline by Chugai Pharmaceutical Co Ltd, H2 2020

Hypoparathyroidism – Pipeline by Eli Lilly and Co, H2 2020

Hypoparathyroidism – Pipeline by Entera Bio Ltd, H2 2020

Hypoparathyroidism – Pipeline by Extend Biosciences Inc, H2 2020

Hypoparathyroidism – Pipeline by GC Pharma, H2 2020

Hypoparathyroidism – Pipeline by ProLynx LLC, H2 2020

Hypoparathyroidism – Pipeline by Sigilon Therapeutics Inc, H2 2020

Hypoparathyroidism – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2020

Hypoparathyroidism – Dormant Projects, H2 2020

List of Figures

List of Figures

Number of Products under Development for Hypoparathyroidism, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports